1,593
Views
0
CrossRef citations to date
0
Altmetric
Clinical Study

Forecast and verification of the active compounds and latent targets of Guyuan decoction in treating frequently relapsing nephrotic syndrome based on network pharmacology

, , , &
Article: 2184654 | Received 13 Apr 2022, Accepted 18 Feb 2023, Published online: 03 Mar 2023

References

  • Kallash M, Smoyer WE, Mahan JD. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr. 2019;7:178.
  • Mühlig AK, Lee JY, Kemper MJ, et al. Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects. JCM. 2019;8(6):860.
  • Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158–169.
  • Schijvens AM, Dorresteijn EM, Roeleveld N, et al. REducing STEroids in relapsing nephrotic syndrome: the RESTERN study-protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open. 2017;7(9):e018148.
  • Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830.
  • Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21(2):193–202.
  • Hamasaki Y, Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2177–2185.
  • Iijima K, Hamahira K, Tanaka R, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61(5):1801–1805.
  • Guo W, Huang J, Wang N, et al. Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma. Front Pharmacol. 2019;10:1185.
  • He LZ, Sheng LX. Sheng Lixian’s clinical experience in treating children with relapsing nephrotic syndrome by stages. Zhejiang JITCWM. 2020;30(2):94–95.
  • Du Wensen WY. Guyuan decoction on microcirculation disorder of diabetic nephropathy. World Chinese Med. 2017;12(07):1587–1589 + 1593.
  • Qun C. Clinical effect of Guyuan decoction and irbesartan in nephrotic syndrome. Journal of China Prescription Drug. 2020;18(01):124–125.
  • Wen X, Wang W, Zheng M, et al. The potential mechanism of Astragali Radix in the treatment of children with nephrotic syndrome. Transl Pediatr. 2021;10(9):2298–2306.
  • Lee SM, Lee YJ, Yoon JJ, et al. Effect of poria cocos on puromycin aminonucleoside-induced nephrotic syndrome in rats. Evid Based Complement Alternat Med. 2014;2014:1–12.
  • Xia P, Gao K, Xie J, et al. Data mining-based analysis of Chinese medicinal herb formulae in chronic kidney disease treatment. Evid Based Complement Alternat Med. 2020;2020:9719872.
  • Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110–1111.
  • Baptista R, Bhowmick S, Shen J, et al. Molecular docking suggests the targets of anti-mycobacterial natural products. Molecules. 2021;26(2):475.
  • Yang H, Fan Y, Cheng J, et al. Network pharmacology-based prediction of active ingredients and potential targets of ShengDiHuang decoction for treatment of dysfunctional uterine bleeding. Evid Based Complement Alternat Med. 2020;2020:7370304.
  • Yao ZM, Chen WD, Yang ZH, et al. Research progress in atractylodes macrocephala and predictive analysis on Q-marker. Chin Tradit Herb Drugs. 2019;50(19):4796–4807.
  • Xin G, Li X, Huang XW. Research progress on chemical constituents and pharmacological action of radix sileris. Jilin J Chin Med. 2018;11(38):1323–1325.
  • Tang M, Xu XF. Advances in studies on chemical constituents and pharmacological effects of medicinal astragalus. Guid J Tradit Chin Med Pharm. 2018;24(20):117–122.
  • Bi LM, Chen YL. Review on glycyrrhizae Radix et Rhizoma treatment of kidney disease. Chin J Exp Tradit Med Formulae. 2015;21(11):228–231.
  • Li B, Rui J, Ding X, et al. Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158–168.
  • Kang KP, Park SK, Kim DH, et al. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol Dial Transplant. 2011;26(3):814–822.
  • Yong C, Zhang Z, Huang G, et al. Exploring the critical components and therapeutic mechanisms of Perilla frutescens L. in the treatment of chronic kidney disease via network pharmacology. Front Pharmacol. 2021;12:717744.
  • Meng XM, Li HD, Wu WF, et al. Wogonin protects against cisplatin-induced acute kidney injury by targeting RIPK1-mediated necroptosis. Lab Invest. 2018;98(1):79–94.
  • Feng D, Li XR, Wang ZY, et al. Integrated UPLC-MS and network pharmacology approach to explore the active components and the potential mechanism of Yiqi Huoxue decoction for treating nephrotic syndrome. Front Pharmacol. 2021;12:775745.
  • Yuan P, Sun X, Liu X, et al. Kaempferol alleviates calcium oxalate crystal-induced renal injury and crystal deposition via regulation of the AR/NOX2 signaling pathway. Phytomedicine. 2021;86:153555.
  • Hao J, Hu H, Liu J, et al. Integrated metabolomics and network pharmacology study on immunoregulation mechanisms of panax ginseng through macrophages. Evid Based Complement Alternat Med. 2019;2019:3630260.
  • Huang L, Jiang X, Gong L, et al. Photoactivation of Akt1/GSK3β isoform-specific signaling axis promotes pancreatic β-cell regeneration. J Cell Biochem. 2015;116(8):1741–1754.
  • Kim IY, Lee MY, Park MW, et al. Deletion of Akt1 promotes kidney fibrosis in a murine model of unilateral ureteral obstruction. Biomed Res Int. 2020;2020:6143542.
  • Wang XW, Tian RM, Yang YQ, et al. Tripterygium glycoside fraction n2 ameliorates adriamycin-induced nephrotic syndrome in rats by suppressing apoptosis. J Ethnopharmacol. 2020;257:112789.
  • Liao Y, Tan RZ, Li JC, et al. Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting mincle/syk/NF-Kappa B signaling pathway. Drug Des Dev Ther. 2020;14:1455–1468.
  • Nickavar A, Valavi E, Safaeian B, et al. Predictive value of serum interleukins in children with idiopathic nephrotic syndrome. Iran J Allergy Asthma Immunol. 2020;19(6):632–639.
  • Wu XQ, Zhang DD, Wang YN, et al. AGE/RAGE in diabetic kidney disease and ageing kidney. Free Radical Biol Med. 2021;171:260–271.
  • Kho MC, Park JH, Han BH, et al. Plantago asiatica L. ameliorates puromycin aminonucleoside-induced nephrotic syndrome by suppressing inflammation and apoptosis. Nutrients. 2017;9(4):386.
  • Lu C, Zheng SF, Liu J. Forsythiaside a alleviates renal damage in adriamycin-induced nephropathy. Front Biosci (Landmark Ed). 2020;25:526–535.
  • Li X, Qi D, Wang MY, et al. Salvianolic acid a attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling inhibition. J Ethnopharmacol. 2021;279:114351.